<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/8E150C14-2FAC-47C2-B43A-BD1778ECF096"><gtr:id>8E150C14-2FAC-47C2-B43A-BD1778ECF096</gtr:id><gtr:name>Haemaflow Limited</gtr:name><gtr:address><gtr:line1>SUITE 5 ROOM 403 ILS PHASE 2 , SWANSEA UNIVERSITY SINGLETON PARK</gtr:line1><gtr:city>SWANSEA</gtr:city><gtr:postCode>SA2 8PP</gtr:postCode><gtr:region>Wales</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8E150C14-2FAC-47C2-B43A-BD1778ECF096" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>8E150C14-2FAC-47C2-B43A-BD1778ECF096</gtr:id><gtr:name>Haemaflow Limited</gtr:name><gtr:address><gtr:line1>SUITE 5 ROOM 403 ILS PHASE 2 , SWANSEA UNIVERSITY SINGLETON PARK</gtr:line1><gtr:city>SWANSEA</gtr:city><gtr:postCode>SA2 8PP</gtr:postCode><gtr:region>Wales</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>102000.0</gtr:offerGrant><gtr:projectCost>145034.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0B221B90-059F-4638-A550-028CF7C26A9E"><gtr:id>0B221B90-059F-4638-A550-028CF7C26A9E</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Llewellyn</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=130997"><gtr:id>ACF901D6-2F85-436E-AA49-7DE17BDBC2EB</gtr:id><gtr:title>Improving Blood Transfusion</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Feasibility Studies</gtr:grantCategory><gtr:grantReference>130997</gtr:grantReference><gtr:abstractText>Donated blood deteriorates in storage so that it no longer carries oxygen efficiently. After transfusion, it can take 48 hrs to become fully reactivated.Donated blood may initially reduce the oxygen-carrying efficiency of thepatient?s own blood. The longer the blood is stored, the greater the risk. Our objective is to investigate a technology that promises to reduce, or reverse, deterioration in storage.
The major benefits in extending the activelife of donated blood are:
? the risk to the patient is reduced and
? an extended shelf-life reduces wastage.
The novel technology passes blood over a membrane impervious to blood, but through which gases can pass. In this way, the concentrations of gases in theblood can be accurately controlled.</gtr:abstractText><gtr:fund><gtr:end>2013-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2012-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>102000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">130997</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>